Imprimis Pharmaceuticals, Inc.
6
0
0
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 70/100
50.0%
3 terminated/withdrawn out of 6 trials
50.0%
-36.5% vs industry average
100%
6 trials in Phase 3/4
67%
2 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (6)
Prophylactic Treatment: Lessdrops™ vs Standard Drops Regimen
Role: collaborator
Economic Impact of Dropless Therapy Versus Usual Care for Cataract Surgery: A Real-World Study.
Role: collaborator
Use of Topical Tranexamic Acid and Bacitracin in Dialysis Patients
Role: collaborator
Efficacy and Safety of Impracor (Ketoprofen 10% Cream) Compared With Placebo in the Treatment of Acute Pain (Flare) Associated With Osteoarthritis of the Knee
Role: lead
Ketoprofen 10% Cream for Treatment of Pain Associated With Mild to Moderate Acute Soft Tissue Injury
Role: lead
Ketoprofen 10% Cream for Treatment of Pain Associated With Mild to Moderate Acute Soft Tissue Injury
Role: lead
All 6 trials loaded